LEADER 05603nam 2200757Ia 450 001 9910141315803321 005 20200520144314.0 010 $a9786613654137 010 $a9781119961000 010 $a1119961009 010 $a9781280677205 010 $a1280677201 010 $a9781119958338 010 $a1119958334 010 $a9781119958321 010 $a1119958326 035 $a(CKB)2670000000161890 035 $a(EBL)822592 035 $a(OCoLC)782918801 035 $a(SSID)ssj0000622303 035 $a(PQKBManifestationID)11387865 035 $a(PQKBTitleCode)TC0000622303 035 $a(PQKBWorkID)10637983 035 $a(PQKB)10869776 035 $a(MiAaPQ)EBC822592 035 $a(Au-PeEL)EBL822592 035 $a(CaPaEBR)ebr10546595 035 $a(CaONFJC)MIL365413 035 $a(Perlego)1011551 035 $a(EXLCZ)992670000000161890 100 $a20110711d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aPharmacotherapy of child and adolescent psychiatric disorders /$f[edited by] David Rosenberg and Samuel Gershon 205 $a3rd ed. 210 $aChichester, West Sussex $cJohn Wiley & Sons, Inc.$d2012 215 $a1 online resource (475 p.) 300 $aDescription based upon print version of record. 311 08$a9780470973769 311 08$a0470973765 320 $aIncludes bibliographical references and index. 327 $aPharmacotherapy of Child and Adolescent Psychiatric Disorders; List of Contributors; Foreword; Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology; References; Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth; Introduction; Prevalence and trends for medications prescribed for ADHD; Nonstimulant medications for ADHD; Antidepressant medication; Antipsychotic medication; Alpha-agonists; Anticonvulsant "mood stabilizers"; Concomitant psychotropic medication; Preschool psychotropic medication use 327 $aInternational patterns of psychotropic medication for youthConclusion; References; Chapter 3 Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry; Introduction; Extent of off-label prescribing; Need for psychoactive drug treatments for children and adolescents; Legislation supporting pediatric drug development; Recommendations to follow when considering off-label prescribing; References; Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology; What is a generic drug?; Why are we discussing generic drugs?; Basic requirements for generic drugs 327 $aThe status of regulations regarding generic drugs and childrenAbbreviated new drug application (ANDA) requirements; Pediatric assessments of adult drugs (history up to current status); Best Pharmaceuticals for Children Act; Pediatric Research Equity Act; Intersection of requirements for generics and pediatric assessment; Future directions; Concluding thoughts; References; Chapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology; Introduction; Basic concepts in pharmacokinetics; Dosing considerations for psychoactive drugs in children; Summary; References 327 $aChapter 6 PsychostimulantsIntroduction; Epidemiology of stimulant use; Structure and biochemical mechanism of action; Neuroimaging studies of stimulant effects; Studies of short-term efficacy; Studies of long-term efficacy; Clinical use; Common side-effects; Cardiovascular safety issues; Growth suppression; Substance use and diversion; Comparison with nonstimulant treatment; Treatment of comorbidity; Pharmacogenetics; Conclusions; References; Chapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders 327 $aTricyclic antidepressants (TCAs)Drug interactions, contraindications; Monoamine oxidase inhibitors (MAOIs); General summary; References; Chapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs); Pharmacokinetics; Initiation and titration; Indications and efficacy; Adverse effects; Withdrawal; References; Chapter 9 Novel (Atypical) Antidepressants; Novel (atypical) antidepressants; General overview; Bupropion; Duloxetine; Mirtazapine; Trazodone; Venlafaxine; Desvenlafaxine; Alternative treatments; Summary; References; Chapter 10 Antipsychotic Agents; Introduction; Chemical properties 327 $aTypical antipsychotics 330 $aThis book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo 606 $aPediatric psychopharmacology 606 $aAntipsychotic drugs 615 0$aPediatric psychopharmacology. 615 0$aAntipsychotic drugs. 676 $a618.92/8918 676 $a618.928918 701 $aRosenberg$b David R$085246 701 $aGershon$b Samuel$0896984 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910141315803321 996 $aPharmacotherapy of child and adolescent psychiatric disorders$92004220 997 $aUNINA